摘要:
This disclosure relates to methods of creating dideoxynucleotide termination frequency (DTF) normalized landscape matrices and time/intensity (TI) normalized landscape matrices, and various applications of the normalized landscape matrices for genomic surveillance, identification, and monitoring of humans, animals, plants, cells and bacteria.
摘要:
The presently disclosed subject matter relates to antagonists of PTEN and methods of using the same. In particular, the presently disclosed subject matter provides for PTEN antagonist peptides for use in treating central nervous system disorders. In an exemplary embodiment, the presently disclosed subject matter provides methods for promoting nerve fiber growth in a subject by administering to the subject a therapeutically effective amount of a PTEN antagonist peptide.
摘要:
A material derived from sea cucumber collagen fibrils is suitable for use in corneal replacements or as an implantable contact lens. To produce material, the collagen fibrils are centrifuged into orthogonal stacks of lamellae comprised of aligned fibrils. The resulting structure is a transparent film of arbitrary thickness very similar in structure to mammalian corneal tissue.
摘要:
An internal fixator apparatus comprises a barrel member having a bone interface adapted to be anchored to a first part of a bone in an extramedullary connection. A piston member has a bone interface adapted to be anchored to a first part of a bone, the piston member including a threaded nut portion, the barrel member and the piston member being operatively connected to concurrently form a joint whereby the barrel member and the piston member are displaceable at least in translation relative to one another. A fixator mechanism is inside the barrel member and the piston member, the fixator mechanism comprising at least a leadscrew threadingly engaged with the threaded nut portion, and at least one magnet connected to the leadscrew to rotate concurrently therewith, the magnet being rotatingly received in the barrel member.
摘要:
The disclosure describes methods of making high-strength NDGA collagen and associated methods of preparing collagen preparatory material and medical bioprostheses.
摘要:
The disclosure describes implantable medical products, that include dry or partially hydrated biocompatible constructs comprising collagen fibers configured to expand in situ after implantation to frictionally engage a bone tunnel wall to thereby affix the construct in the bone tunnel.
摘要:
Method for performing spinal correction surgery. The method includes creating at least one access opening in a patient, and implanting a plurality of anchor devices through the at least one access opening onto a plurality of corresponding vertebral bodies. Each anchor device has a channel defined therein. The method further includes disposing a tether into the channel of each of the plurality of anchor devices. A first end portion of the tether is secured to a first of the plurality of anchor devices. Additionally, the method includes translating the vertebral body corresponding to the selected anchor device using a pusher tool. Furthermore, the method includes applying a tension to the tether using a tensioner.
摘要:
A material derived from sea cucumber collagen fibrils is suitable for use in corneal replacements or as an implantable contact lens. To produce material, the collagen fibrils are centrifuged into orthogonal stacks of lamellae comprised of aligned fibrils. The resulting structure is a transparent film of arbitrary thickness very similar in structure to mammalian corneal tissue.
摘要:
The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.